Status:
COMPLETED
Tranexamic Acid in Pediatric Cardiac Surgery
Lead Sponsor:
Okayama University
Conditions:
Blood Loss
Congenital Heart Disease
Eligibility:
All Genders
2-18 years
Phase:
NA
Brief Summary
Tranexamic acid(TXA) is an antifibrinolytic agent to reduce blood loss in cardiac surgery. Previous seven RCTs comparing effects of TXA in pediatric cardiac surgery showed conflict results. The reason...
Eligibility Criteria
Inclusion
- children undergoing elective cardiac surgery with cardiopulmonary bypass
Exclusion
- neonate born within 1 month
- preoperative inotropes
- preoperative mechanical ventilation
- preexisting coagulation disorder
- reoperation within 48 hours
- significant liver or kidney disease
- known allergy to TXA
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00994994
Start Date
January 1 2006
End Date
April 1 2008
Last Update
October 14 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.